Therapy News and Research

RSS

Nuvilex discusses Cell-in-a-Box technology used for pancreatic cancer clinical trial

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, discussed today the proprietary Cell-in-a-Box technology, being acquired from SG Austria, that was used for the pancreatic cancer clinical trial and may have an effect on downstream micro metastatic disease.

14 Mar 2012

Azithromycin associated with lower duration of bacterial carriage in E. coli outbreak

In the E coli outbreak in Germany in May 2011, treatment with azithromycin was associated with a lower frequency of long-term carriage of the bacteria and shorter duration of shedding of the bacteria in stool specimens, according to a study in the March 14 issue of JAMA.

14 Mar 2012

The two sides of pain

"Pain is both a curse and a blessing", says Jürgen Sandkühler, Head of the Department of Neurophysiology at the Centre for Brain Research at the MedUni Vienna ahead of the international "Brain Awareness Week", being held from the 12th to the 16th of March. On the one hand, pain has an important protective function for humans.

14 Mar 2012

New study to better understand role of the immune system in stroke

Stroke and other diseases and injuries to the brain are often followed by inflammation, caused by a reaction of the body's immune system. This reaction has been seen as something that must be combated, but perhaps the immune system could in fact help with recovery following a stroke. A major new EU project, led by Lund University in Sweden and the Weizmann Institute in Israel, is going to study this question.

14 Mar 2012

MRI perfusion imaging can help determine brain tumor progression

Gliomas, the most common malignant brain tumors in adults, can be difficult to treat because of their aggressive and invasive nature. In treating patients with gliomas, it is increasingly important that doctors be able to detect tumor changes early when there's a better chance for recovery.

14 Mar 2012

Homeopathy could soon be declared “baseless and unethical” in Australia

Homeopathy is a branch of alternative medicine based on the principles of “like-cures-like” and “ultra-dilutions”. The first principle says substances that can cause symptoms can be used in diluted form to treat the same symptom in an illness, and the second says the more dilute a substance is, the more potent it is.

14 Mar 2012

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

Botox - a potential for therapy of weak bladders in women

The study, published in the journal European Urology, was carried out at eight uro-gynecology centers in the UK from 2006 to 2009 by researchers from the University of Leicester. A total of 240 women were split into two groups, with 122 women given Botox and 118 receiving a dummy treatment. Researchers found improvements across a range of symptoms, including wetting oneself and feeling a need to rush to the toilet, and how often the women 'leaked' urine.

13 Mar 2012

FDA panel favors continued research on novel pain medicine

A panel of experts for the U.S. Food and Drugs Administration (FDA) this Monday recommended that the federal government should allow continued testing of an experimental class of pain drugs for arthritis, despite links to bone decay and joint failure.

13 Mar 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

New recovery protocol treats heart failure patients with LVADs

Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.

13 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

Diacetylmorphine more cost-effective than MMT in treating street heroin users

Medically prescribed heroin is more cost-effective than methadone for treating long-term street heroin users, according to a new study by researchers at Providence Health Care and the University of British Columbia.

13 Mar 2012

FTY720 improves locomotor recovery in mice with SCI

A new study suggests that administering FTY720, an oral drug that has shown promise in trials for human multiple sclerosis, significantly improves locomotor recovery in mice with spinal cord injury.

13 Mar 2012

Some adaptive motion trainers may still impose high stresses on the knee

New research conducted by the University of Wisconsin - La Crosse Department of Physical Therapy calls into question the conventional wisdom that non-impact cardio machines, such as adaptive motion trainers (AMTs), apply minimum stress to the joints.

13 Mar 2012

Majority of physicians utilize genetic testing, finds report

A new report by UnitedHealth Group's Center for Health Reform & Modernization finds that a majority of physicians are utilizing genetic testing. The report, titled "Personalized Medicine: Trends and prospects for the new science of genetic testing and molecular diagnostics," presents new findings on how genetic tests can help diagnose disease, target prevention, and ensure that patients receive the medicines that will best treat their conditions.

12 Mar 2012

Researchers unlock mystery of how an inflammatory molecule is produced in the body

Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.

12 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

Salk scientists' discovery explains how a class of chemotherapy drugs works

The well-being of living cells requires specialized squads of proteins that maintain order. Degraders chew up worn-out proteins, recyclers wrap up damaged organelles, and-most importantly-DNA repair crews restitch anything that resembles a broken chromosome. If repair is impossible, the crew foreman calls in executioners to annihilate a cell. As unsavory as this last bunch sounds, failure to summon them is one aspect of what makes a cancer cell a cancer cell.

12 Mar 2012